Geographically North America dominated global protein therapeutics market, with approximately half of the market in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing incidences of chronic diseases, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing population in developing nations such as China, and India in this region. Among all the type, Monoclonal Antobodies (mAbs) segment has the highest market share in global protein therapeutics market due to higher prevalence of cancer patients.
This report identifies the global protein therapeutics market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global protein therapeutics market.
This report segments global protein therapeutics market on the basis of type, functionality and regional market as follows:
Protein Therapeutics Market, By Type: Monoclonal Antobodies (mAbs), Erythropoietin (EPO), Insulin, Interferon (IFN), Human Growth Hormone (HGH), Follicle Stimulating Hormone (FSH), Blood Clotting Factors, and Others
This report has been segmented by functionality of protein therapeutic such as: Group I: Enzymatic or Regulatory Activity, Group II: Special Targeting Activity, Group III: Protein Vaccines, and Group IV: Protein Diagnostics
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the protein therapeutics market. Some of the major companies’ profiles in detail are as follows:
Eli Lilly & Company
Group Biogen Idec Inc.
Merck Serono S.A.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Protein Therapeutics Market– Market Forces
4.1.1. Development of novel and efficient drugs
4.1.2. Growing incidences of chronic disorders such as cardiovascular, cancer, diabetes, and others
4.2.1. Higher cost of research and development
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Protein Therapeutics Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Protein Therapeutics Market, By Type
6.1. Monoclonal Antobodies (mAbs)
6.2. Erythropoietin (EPO)
6.4. Interferon (IFN)
6.5. Human Growth Hormone (HGH)
6.6. Follicle Stimulating Hormone (FSH)
6.7. Blood Clotting Factors
7. Protein Therapeutics Market, By Functionality
7.1. Group I: Enzymatic or Regulatory Activity
7.2. Group II: Special Targeting Activity
7.3. Group III: Protein Vaccines
7.4. Group IV: Protein Diagnostics
8. Protein Therapeutics Market, By Geography
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Protein Therapeutics – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Eli Lilly & Company
10.2. Abbott Laboratories
10.3. Group Biogen Idec Inc.
10.4. Merck Serono S.A.
10.5. Amgen Inc.
10.7. Johnson & Johnson
10.8. Novo Nordisk
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights